Antengene Corporation Limited (“ Antengene “, SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing ...

A new study shows strong alignment between real-world outcomes and those seen in clinical trials among a broad population of patients with relapsed or refractory multiple myeloma. In the first study ...

A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, ...

Andrew Moyens, 52, knew something was wrong when he was too tired to take down the Christmas tree - but little did he know at ...

A new cell therapy, targeting CD7 on leukaemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukaemia (T-ALL) who have exhausted all standard treatment ...

Research has shown that among patients with advanced non-small cell lung cancer, early palliative care delivered by video is ...

A new study reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment.

A new study published in Cell Reports Medicine reveals critical insights into the role of gamma-delta T cells across 33 ...

BriaCell Therapeutics announced that its Bria-IMT cell therapy, plus an immune checkpoint inhibitor regimen, achieved ...

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today ...

Researchers at Medicine have uncovered a new mechanism that controls a special group of immune cells known as regulatory ...

In this webinar, Christoph Herbel will discuss multiplexed spatial analyses that identify ovarian tumor antigens and CAR T ...